top of page
Browse by category
Search


Improving our understanding of endoscopic sleeve gastroplasty
The British Obesity & Metabolic Specialist Society (BOMSS) recently revealed that endoscopic sleeve gastroplasty (ESG) procedural data will be incorporated into the Society’s National Bariatric Surgery Registry (NBSR). In this interview, Mr Omar Khan, Chair of the NBSR Committee, and Mr Jamie Kelly, who has performed over 500 ESG procedures, discuss the importance of the registry, why ESG plays a crucial role in the armamentarium of a bariatric specialist and the future possi


FitForMe launches new supplements addressing protein deficiency, digestive issues and nutritional deficiencies during obesity treatment
More than one billion people worldwide are living with obesity. Lifestyle intervention programmes, GLP-1 medications and bariatric surgery can be transformative, but they do not exist in a nutritional vacuum. Deficiencies are common among people affected by obesity before treatment begins, and surgery or medication can make them harder to ignore. Patients arrive underprepared, find little nutritional support built into their care, and are largely left to manage the consequenc


MBS is associated with greater long-term heart risk reduction than GLP-1 medications
Both metabolic and bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonist (GLP-1RA) medications improve cardiovascular health in people with obesity, but surgery was associated with significantly greater reductions in long-term cardiovascular risk, according to a study by researchers from the Mayo Clinic. Importantly, researchers say the findings are not about choosing one treatment over another, but about better aligning treatment decisions with long-term healt


Inconsistent use of GLP-1s may make the drug less effective
Inconsistent use of some GLP-1 weight-loss medications, like Ozempic and Wegovy, may significantly lessen their effectiveness, according to a preclinical study from researchers at the Perelman School of Medicine at the University of Pennsylvania. The study showed that each time overweight mice stopped and restarted GLP-1s, they dropped less and less weight compared their original weight-loss. “The effectiveness of these medications may depend heavily on consistency,” said Dr


Olympus gains FDA clearance for POWERSEAL Open Extended Jaw Device
Olympus Corporation has received FDA 510(k) clearance for the POWERSEAL Open Extended Jaw Sealer/Divider. This latest edition to the Olympus POWERSEAL advanced bipolar surgical energy portfolio supports clinical needs for precision, efficiency and control during surgery. POWERSEAL Open Extended Jaw Sealer/Divider The POWERSEAL Open Extended Jaw Sealer/Divider joins three 5mm devices in the POWERSEAL portfolio. These 5mm devices are offered in three jaw configurations, each av


Obesity leaves a lasting memory in immune cells
People who live with obesity are "tagging" a memory of being overweight on a key part of the immune system - leaving people with ongoing risk of obesity-related conditions years after losing weight, according to a 10-year-long study led by University of Birmingham, UK. A European research team led by Professor Claudio Mauro from the University of Birmingham has shown that immune cells known as helper T cells (or CD4+ lymphocytes) carry a long memory of obesity. "The findings


Ascletis completes enrolment in US Phase II Study of ASC30
Ascletis Pharma has completed enrolment in its 13-week US Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). T2D is the second indication for ASC30, following its first indication of obesity. Topline data from the Phase II study for the treatment of T2D are expected in the third quarter of 2026. The Phase II study is a 13-week, randomised, double-blind, placebo-controlled and multi-cent


Concomitant laparoscopic cholecystectomy during bariatric surgery is safe and feasible
A prospective randomised controlled pilot study by researchers from Mansoura University, Mansoura, Egypt, has demonstrated that concomitant laparoscopic cholecystectomy (LC) during bariatric surgery in patients with morbidly obesity with pre-existing gallstones is safe and feasible. Although concomitant LC results in longer operative time (mean increase of 23.75 min) and higher immediate postoperative pain scores, the researchers noted that these differences do not translate


J&J gains CE Mark Approval for ETHICON 4000 Stapler
Johnson & Johnson has received European CE Mark approval for its new ETHICON 4000 Stapler, an advanced surgical stapler designed to deliver reliable staple line integrity across a wide range of tissue thickness. ETHICON 4000 Stapler With proprietary 3D Stapling Technology, a redesigned end-effector and streamlined reload options, the ETHICON 4000 and ETHICON 3D Reloads are certified for use in open and laparoscopic surgery across the European Union. The new advanced stapling


Improving patient compliance in multivitamin supplementation
Compliance with any multivitamin and/or protein supplement regimen can be difficult, especially after bariatric surgery. Nutritional deficiency, as a result of gastric bypass surgery, is a substantial possibility without any form of supplementation and even with compliance to standard multivitamin supplementation.1 Problematic adherence The multivitamin supplementation (MVS) regimen could have a major impact on patient adherence,
Browse by tag






bottom of page
